Results 151 to 160 of about 195,466 (218)
Wake-Up Stroke Due to Middle Cerebral Artery Occlusion and the Decision Between Medical Management and Stenting: A Case Report. [PDF]
Vargas OF +5 more
europepmc +1 more source
ABSTRACT Objectives To evaluate the feasibility and short‐term outcomes of transcatheter aortic valve replacement (TAVR) using balloon‐expandable Sapien valves in patients with prior endovascular aortic stent grafts. Methods We conducted a single‐center, retrospective study of 23 patients with prior endovascular aortic stent grafts who underwent TAVR ...
Iad Alhallak +8 more
wiley +1 more source
Protocol for a murine transient middle cerebral artery occlusion model with local intra-arterial drug delivery. [PDF]
Lee JJ, Murphy MP, Krieg T.
europepmc +1 more source
The internal mammary artery as an alternative graft for internal maxillary artery-middle cerebral artery bypass: illustrative case. [PDF]
Ramírez-Andrade JJ +7 more
europepmc +1 more source
Balancing Time and Risk: Temporary Arterial Occlusion in Middle Cerebral Artery Aneurysm Surgery. [PDF]
Geiger P +4 more
europepmc +1 more source
Early decompressive hemicraniectomy combined with mild hypothermia treatment for malignant middle cerebral artery infarction. [PDF]
Chen J +9 more
europepmc +1 more source
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri +12 more
wiley +1 more source
A Rapidly Progressive Thrombosed Middle Cerebral Artery Aneurysm After Endovascular Treatment. [PDF]
Matsushita R +4 more
europepmc +1 more source
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao +27 more
wiley +1 more source

